2007Hainan yixueRequires access

Chinical efficacy of edaravone on acute cerebral hemorrhage

Wang Guodong

Open publisher page 1 citations

Abstract

Objective To evaluate the efficacy of edaravone,a novel hydroxy-free radical scavenger,on the treatment of acute cerebral hemorrhage(CH). Methods 71 CH cases enrolled within 48h of onset were divided into treatment group(n=36) and control group(n=35) randomly. Edaravone was infused at a dose of 30mg,twice a day,for 14 days. Meanwhile,the dehydrater(mannitol and or albumin) were taken as basic treatment. The therapies of the placebo group were similar to those of Edaravone group except for Edaravone. Before treatment and at 30th day after treatment,the neurological deficits and activities of daily living were evaluated using European Stroke Scale(ESS). All the patients were followed up for survival at 30th dav the increase rate of ESS was evaluated. There were significan difference between Edaravone group(48.2±16.4)% and the placebo group (29.7±11.1)% (P0.001). Conclusions Edaravone is a new effective neuroprotective agent for treating CH.

About this research paper

What this paper is about

Objective To evaluate the efficacy of edaravone,a novel hydroxy-free radical scavenger,on the treatment of acute cerebral hemorrhage(CH). Methods 71 CH cases enrolled within 48h of onset were divided into treatment group(n=36) and control group(n=35) randomly. Edaravone was infused at a dose of 30mg,twice a day,for 14 days. Meanwhile,the dehydrater(mannitol and or albumin) were taken as basic treatment. The therapies of the placebo group were similar to those of Edaravone group except for Edaravone. Before treatment and at 30th day after treatment,the neurological deficits and activities of daily living were evaluated using European Stroke Scale(ESS). All the patients were followed up for survival at 30th dav the increase rate of ESS was evaluated. There were significan difference between Edaravone group(48.2±16.4)% and the placebo group (29.7±11.1)% (P0.001). Conclusions Edaravone is a new effective neuroprotective agent for treating CH.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the efficacy of edaravone,a novel hydroxy-free radical scavenger,on the treatment of acute cerebral hemorrhage(CH). Methods 71 CH cases enrolled within 48h of onset were divided into treatment group(n=36) and control group(n=35) randomly. Edaravone was infused at a dose of 30mg,twice a day,for 14 days. Meanwhile,the dehydrater(mannitol and or albumin) were taken as basic treatment. The therapies of the placebo group were similar to those of Edaravone group except for Edaravone. Before treatment and at 30th day after treatment,the neurological deficits and activities of daily living were evaluated using European Stroke Scale(ESS). All the patients were followed up for survival at 30th dav the increase rate of ESS was evaluated. There were significan difference between Edaravone group(48.2±16.4)% and the placebo group (29.7±11.1)% (P0.001). Conclusions Edaravone is a new effective neuroprotective agent for treating CH.

Key concepts: Edaravone, Medicine, Free radical scavenger, Placebo, Anesthesia, Mannitol, Placebo group, Neuroprotection

Related papers

Back to paper searchBrowse research topicsOriginal source
Chinical efficacy of edaravone on acute cerebral hemorrhage — Research Paper | ScholarLens